These findings highlight that while larger tumor size and lymph node involvement remain the strongest predictors of poor prognosis, SOX2 overexpression may confer a survival advantage, whereas NANOG expression does not appear to influence recurrence-related outcomes. The gene discussed is NANOG; the disease is neoplasm.